UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private
Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of October 2026
Commission file number: 001-42375
Polyrizon Ltd.
(Translation of registrant’s name into English)
8 Ha-Pnina Street
Raanana, 4321545, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
Attached hereto and incorporated herein is the
Registrant’s press release issued on October 27, 2026, titled “Polyrizon Announces Successful Completion Enrollment of all
120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker.”
The first, second, third and fifth paragraphs
of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into
the Registrant’s Registration Statements on Form S-8 (File No. 333-284410, 333-288923
and 333-299350) and Form F-3
(333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker” |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Polyrizon Ltd. |
| |
|
| Date: October 27, 2026 |
By: |
/s/ Tomer Izraeli |
| |
Name: |
Tomer Izraeli |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Polyrizon Announces Successful Completion Enrollment
of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
All 120 planned participants randomized across
five clinical sites in the United States
Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon
Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the
development of innovative intranasal hydrogels, today announced the successful completion of patient enrollment and randomization in its
U.S. multicenter clinical study evaluating NASARIX, the Company’s proprietary investigational nasal hydrogel product candidate designed
to provide protection against airborne allergens.
The study has reached its planned enrollment target, with 120 participants
randomized across five clinical research sites in the United States. A total of 144 individuals were screened to achieve the enrollment
target.
The clinical study is designed to evaluate the performance of NASARIX
in adults with allergic rhinitis. NASARIX utilizes Polyrizon’s proprietary Capture and Contain™ technology, which forms a protective
mucoadhesive barrier within the nasal cavity, designed to limit allergen contact with the nasal mucosa.
“Completing enrollment and randomization of all 120 participants
represents an important milestone in the clinical development of NASARIX,” said Tomer Izraeli, Chief Executive Officer of Polyrizon.
“With enrollment now complete across five U.S. clinical sites, we are focused on completing the remaining study activities and advancing
toward the clinical data readout. We believe that this achievement marks another important step in our efforts to bring our innovative
nasal barrier technology closer to patients.”
The randomized, controlled clinical study compares NASARIX with a saline
control and is designed to assess its performance in managing symptoms associated with allergic rhinitis. Following completion of the
treatment and follow-up periods, the Company expects to proceed with data review and analysis in accordance with the clinical study protocol.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the
development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment
barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s
proprietary Capture and Contain™, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building
blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment
barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion
and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology,
which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs,
as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates”
and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the completion of the remaining study activities, the timing and outcome of the clinical
data readout, data review and analysis, the design and potential performance and benefits of NASARIX, potential regulatory submissions,
and the Company’s plans to continue developing its technology. Forward-looking statements are not historical facts, and are based
upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such
expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations,
beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ
materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting
the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”),
including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December
31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company
assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates
with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,
and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible
for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
